ISEC Lisbon and the Complutense University of Madrid (UCM) have had software that supports the diagnosis and control of childhood myopia patented by the Madrid Intellectual Property Registry.
Patent WO 2021/241884 A1, entitled ‘Digital apparatus and application for treating myopia,’ describes a digital therapy system (Digital Therapeutics – DTx) designed to control and treat childhood myopia, focusing on children and adolescents (under 20 years of age).
The development phase involved collaboration between ISEC Lisbon and the Complutense University of Madrid (UCM). The team includes lecturers and researchers from both institutions, namely Cristina Álvarez Peregrina and Miguel Ángel Sánchez Tena (UCM), as well as Clara Martínez Pérez and Luís Filipe Ferreira Marques Santos (ISEC Lisbon).
‘This system stands out for incorporating physiological (neurohormonal) factors into digital treatment, representing an innovative approach among software-based therapies for myopia. It introduces professional-supervised interaction, with real-time monitoring and continuous personalisation, combining software, hardware and clinical care,’ they said in a statement.
Its practical application, both in Portugal and Spain, can be seen immediately in clinical, educational and research contexts, namely optometry and ophthalmology clinics; clinics and health centres offering paediatric vision assessments; schools with eye screening programmes; and research projects on children’s eye health.
Legal protection is already assured, with the favourable resolution of the copyright registration (Registration M-1430-2025), with the ownership of the exploitation rights shared between the Complutense University of Madrid and ISEC Lisbon.
